🔗 Share this article

This year's Nobel Prize in medical science has been awarded for revolutionary findings that illuminate how the immune system targets harmful infections while sparing the body's own cells.

A trio of esteemed scientists—from Japan Prof. Sakaguchi and American experts Mary Brunkow and Fred Ramsdell—share this accolade.

Their work uncovered specialized "security guards" within the immune system that eliminate malfunctioning immune cells that could harming the organism.

The findings are now enabling new therapies for immune disorders and malignancies.

The winners will share a monetary award valued at 11 million Swedish kronor.

Decisive Findings

"The research has been decisive for comprehending how the immune system operates and the reason we don't all suffer from serious autoimmune diseases," stated the chair of the Nobel Committee.

The team's research address a core question: How does the immune system defend us from countless invaders while keeping our healthy cells intact?

Our body's protection system employs white blood cells that scan for indicators of disease, including pathogens and bacteria it has not met before.

These defenders utilize detectors—called recognition units—that are generated randomly in countless combinations.

This gives the defense network the capacity to fight a wide array of threats, but the unpredictability of the mechanism unavoidably creates immune cells that can attack the body.

Protectors of the Immune System

Scientists previously understood that some of these problematic white blood cells were destroyed in the immune organ—the site where white blood cells develop.

The latest Nobel Prize honors the discovery of T-reg cells—described as the body's "peacekeepers"—which travel through the body to disarm other immune cells that attack the body's own tissues.

We know that this mechanism malfunctions in self-attack conditions such as juvenile diabetes, multiple sclerosis, and RA.

The Nobel panel stated, "The discoveries have laid the foundation for a new field of research and spurred the development of innovative treatments, for instance for cancer and immune disorders."

In malignancies, T-regs prevent the body from attacking the tumor, so studies are focused on lowering their quantity.

In autoimmune diseases, trials are exploring increasing regulatory T-cells so the organism is no longer being harmed. A similar method could also be effective in reducing the risks of transplanted organ rejection.

Innovative Experiments

Professor Sakaguchi, from a Japanese institution, performed tests on rodents that had their thymus removed, causing autoimmune disease.

He demonstrated that introducing defense cells from other mice could prevent the disease—suggesting there was a mechanism for blocking immune cells from harming the host.

Dr. Brunkow, from the a research center in Seattle, and Fred Ramsdell, now at Sonoma Biotherapeutics in San Francisco, were investigating an genetic immune disorder in mice and humans that resulted in the discovery of a genetic factor vital for the way T-regs function.

"The groundbreaking research has revealed how the immune system is controlled by regulatory T cells, stopping it from mistakenly attacking the healthy cells," said a leading biological science expert.

"This work is a remarkable illustration of how basic biological research can have far-reaching consequences for public health."